Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis

Shi, Huijuan; Song, Hongbin; Zhao, Qianying; Tao, Chun-Xia; Liu, Min; Zhu, Qing

doi:10.1097/md.0000000000012398

Cited by 16 publications

(16 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the safety profile has been proved acceptable, efficacy results are varied and elucidation especially for patients with both HPV infection and cervical lesions is limited. [ 54 ]…”

Section: Discussionmentioning

confidence: 99%

Clearance of human papillomavirus infection in patients with cervical intraepithelial neoplasia

et al. 2020

View full text Add to dashboard Cite

Background: There are currently no available standard drugs treating human papillomavirus (HPV) infection, especially for patients with low-grade cervical lesion. Several therapies are explored but the results are inconclusive. The objective of this study was to evaluate the efficacy of reported non-invasive treatments in patients with HPV infection and cervical lesions by meta-analysis. Methods: A comprehensive search of prospective and randomized studies published from April 2000 to April 2020 was conducted in electronic databases. The statistical analyses of the pooled risk ratios (RRs) and the corresponding 95% confidence intervals (95% CIs) were performed using the Revman 5.2 software. Results: Twelve articles including 12 randomized controlled studies and 1 prospective controlled randomized pilot study were enrolled. Therapeutic medications included biological and herbal regimen, interferon regimen and probiotics. The meta-analysis showed the experimental treatments had a statistically significant improvement in HPV clearance rate compared with the controls (RR = 0.71, 95% CI [0.63, 0.80], P < .00001); subgroup analyses stratified by regimen categories were consistent with results in the overall group. Treatment using biological and herbal regimen, interferon regimen or probiotics also resulted in a beneficial outcome in regression rate of cervical lesions compared with the controls (RR = 0.55, 95% CI [0.39, 0.79], P = .001). The trend was more favorable in the probiotics than that in the biological and herbal regimen (RR 0.48 vs 0.72). Conclusion: Treatment of biological and herbal regimen, interferon regimen and probiotics benefit patients who have HPV infection and cervical lesions. Both the clearance of HPV and regression of cervical lesions are significant. More studies with less heterogeneity are needed to draw a concrete conclusion.

show abstract

“…Although the safety profile has been proved acceptable, efficacy results are varied and elucidation especially for patients with both HPV infection and cervical lesions is limited. [ 54 ]…”

Section: Discussionmentioning

confidence: 99%

Clearance of human papillomavirus infection in patients with cervical intraepithelial neoplasia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, six studies that met all the inclusion criteria were used (two randomized controlled trials and four observational studies). The studies were from two countries: one from Mexico 16 and five from China 12,17–20 . These studies included 303 patients, and the pooled effective rate of interferon was 61.50% (95% confidence interval [CI] 0.480–0.749).…”

Section: Resultsmentioning

confidence: 99%

“…With regard to the results of the HPV DNA typing test, the rate of efficacy was defined as the rate of clearance of more than one type of HPV, whereas with regard to the results of the HC2 hrHPV DNA test, it was defined as the rate at which more than 25% of the hrHPV load decreased 12–15 …”

Section: Methodsmentioning

confidence: 99%

REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients

Yang

Teng

Ming

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Background: Persistent high-risk human papillomavirus (hrHPV) infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable. This study aimed at evaluating the therapeutic efficacy of REBACIN® in patients with persistent hrHPV infection. Methods: This study is a combination of a retrospective analysis and a meta-analysis. The retrospective analysis included 364 patients who were persistently infected with HPV for at least twelve months, between September 2015 and February 2019, and only received REBACIN® intervention. HPV DNA typing, HC2 hrHPV DNA, and ThinPrep cytologic tests were performed before and after REBACIN® intervention, to evaluate the therapeutic efficacy. The meta-analysis included trials evaluating the therapeutic efficacy of interferons. Results: After a follow-up period of three to six months, the overall effective rate of REBACIN® was 74.73% (272/364), which was higher than that of interferon (61.50%

show abstract

“…With regard to the results of HPV DNA typing test, the effective rate was defined as the rate of clearance of more than one HPV type, whereas with regard to the results of the HC2 hrHPV DNA test, it was defined as the rate at which more than 25% of hrHPV load decreased [12][13][14][15].…”

Section: Evaluation Of Rebacin® Efficacymentioning

confidence: 99%

REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: a retrospective analysis of 364 patients

Ming

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Persistent high-risk human papillomavirus (hrHPV) infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable. This study aimed at evaluating the therapeutic efficacy of REBACIN® in patients with persistent hrHPV infection.Methods: This study is a combination of a retrospective analysis and a meta-analysis. The retrospective analysis included 364 patients who were persistently infected with HPV for at least twelve months, between September 2015 and February 2019, and only received REBACIN® intervention. HPV DNA typing, HC2 hrHPV DNA, and ThinPrep cytologic tests were performed before and after REBACIN® intervention, to evaluate the therapeutic efficacy. The meta-analysis included trials evaluating the therapeutic efficacy of interferons.Results: After a follow-up period of three to six months, the overall effective rate of REBACIN® was 74.73% (272/364), which was higher than that of interferon (61.50%). The efficacy of REBACIN® was correlated with HPV type (OR: 0.549, 95% CI: 0.367–0.822, P < 0.05) and pretreatment cytology (OR: 0.358, 95% CI: 0.173–0.739, P < 0.05).Conclusions: REBACIN® is potently efficacious at clearing persistent hrHPV infection; hence, it can serve as an optional intervention for persistent hrHPV infection.

show abstract

Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis

Cited by 16 publications

References 49 publications

Clearance of human papillomavirus infection in patients with cervical intraepithelial neoplasia

Clearance of human papillomavirus infection in patients with cervical intraepithelial neoplasia

REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients

REBACIN® is an optional intervention for persistent high-risk human papillomavirus infection: a retrospective analysis of 364 patients

Contact Info

Product

Resources

About